Peritoneal carcinomatosis of colorectal origin Is there a role for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?
نویسنده
چکیده
Siham Zerhouni, MD is a surgical resident with the Department of Surgery, University of British Columbia, Vancouver, and a graduate student in the Division of Experimental Therapeutics, Toronto General Research Institute and Institute of Medical Science, University of Toronto. J. Andrea McCart, MD, MSc, FRCSC is the Director of the Ontario Peritoneal Malignancy Program; associate Professor in the Department of Surgery and Institute of Medical Science at the University of Toronto; and Scientist in the Division of Experimental Therapeutics, Toronto General Research Institute. Corresponding Author: Dr. J. Andrea McCart, Mount Sinai Hospital, 600 University ave, Suite 1225, Toronto, ON, M5G 1X5; Tel: (416) 586-4552; Fax: (416) 586-8392; Email: [email protected]. AbStRACt
منابع مشابه
Cytoreductive surgery and hyperthermic intraperitenoal chemotherapy (HIPEC) for colorectal and appendiceal carcinomas with peritoneal carcinomatosis.
PURPOSE Cytoreductive surgery combined with intraperitoneal chemotherapy has been established as the standard treatment for selected patients with peritoneal malignancy. The purpose of the study was the presentation of the 10- year experience with cytoreductive surgery and intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal and appendiceal origin. METHODS Cli...
متن کاملModern management of peritoneal carcinomatosis of colorectal origin – Is hyperthermic intraoperative peritoneal chemotherapy the treatment of first choice?
Although cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is still considered as “experimental” by many, there is growing evidence that supports its general use in selective patients with peritoneal carcinomatosis of colorectal origin. The selection of patients remains challenging but is the crucial key to achieve optimal oncological results. Recent st...
متن کاملCytoreductive Surgery and HIPEC for Colorectal Cancer: Facing the Facts and Addressing the Issues to Allow for Widespread Acceptance
Despite mounting evidence of the effectiveness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS and HIPEC) at prolonging survival in selected patients with colorectal peritoneal carcinomatosis, there remains a reluctance to explore this combined treatment modality. This is likely to be a result of the perceived morbidity and mortality of such a procedure, with most me...
متن کاملMorbidity and mortality following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy at a tertiary care center: initial experience.
BACKGROUND Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy increases progression-free and overall survival in patients with peritoneal carcinomatosis of appendicular or colorectal origin. The morbidity associated with this procedure is significant (30-52%). This modality is also routinely used in other peritoneal diseases with improvement of outcome. The aim of this study wa...
متن کاملSecond-look surgery plus hyperthermic intraperitoneal chemotherapy for patients with colorectal cancer at high risk of peritoneal carcinomatosis: Does it really save lives?
The treatment of peritoneal carcinomatosis (PC) of colorectal origin with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) has a 5-year recurrence-free or cure rate of at least 16%, so it is no longer labeled as a fatal disease, and offers prolonged survival for patients with a low peritoneal carcinomatosis index. Metachronous PC of colorectal origin is so pred...
متن کامل